Gepirone (Exxua): New Antidepressant FDA Approved for MDD
On Sep 28, 2023: Fabre-Kramer Pharmaceuticals Announcesd the FDA Approval of EXXUA™, the Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults.
Psychiatry Education Forum Academy has summarized this newly approved medication in clinically relevant discussions:
- Indication
- Mechanism of Action
- Lab work needed before initiating the medication
- How to Dose?
- When to use the low dose?
- Drug Interactions to consider?
- Contraindications
- Common side effects
- Pregnancy risk?
WATCH DISCUSSION:
[FOR PEFA MEMBERS]
INTERESTED IN LEARNING MORE?
JOIN PSYCHIATRY EDUCATION FORUM ACADEMY MEMBERSHIP
This is a closed membership for medical professionals only.
- 30+ Courses/Sections: Each chapter within these sections is of direct clinical relevance for your daily practice.
- Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice.
- Coffee Club: contain short discussions with clinical experts in the field of psychiatry.
- Clinical Case Discussions: Discussions of clinical cases from our daily clinical practice.
- Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases.
- Essentials of Inpatient Psychiatry Book: All chapters from this book are included in the academy sections.
- Goal: is to have all important clinically relevant topics in one place for ease of access.
